Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $94.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 8.34% to $94.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.8 million through Dec 2025, up 8.34% year-over-year, with the annual reading at $94.8 million for FY2025, 8.34% up from the prior year.
  • Total Non-Current Liabilities hit $94.8 million in Q4 2025 for Taysha Gene Therapies, down from $96.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $241.1 million in Q3 2023 to a low of $52.3 million in Q2 2024.
  • Historically, Total Non-Current Liabilities has averaged $102.7 million across 4 years, with a median of $96.1 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 150.03% in 2023 and later tumbled 62.64% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $121.2 million in 2022, then dropped by 20.61% to $96.2 million in 2023, then dropped by 9.03% to $87.5 million in 2024, then rose by 8.34% to $94.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TSHA at $94.8 million in Q4 2025, $96.0 million in Q3 2025, and $83.2 million in Q2 2025.